Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart ...

According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...

Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.Don't ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

The biotech industry can be volatile even for relatively large companies. Amgen (NASDAQ: AMGN), one of the more prominent ...

The stock's early-sessions lows when it was down more than 10% had put it on track to be Amgen's (AMGN) worst one-day percentage fall since a 13.4% drop on Oct. 27, 2000, according to Dow Jones Market ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...